Transcription
23RD ANNUALLYNN SAGEBREAST CANCER SYMPOSIUMSEPTEMBER 30 – OCTOBER 2, 2021VIRTUALFOR 2021SYMPOSIUM CHAIRWilliam Gradishar, MDSYMPOSIUM CO-CHAIRMonica Morrow, MDSCIENTIFIC PLANNING COMMITTEENora Hansen, MDKalliopi Siziopikou, MD, PhDJonathan Strauss, MD, MBAVISIT OUR WEBSITE lynnsagebreastcancer.org
Dear Colleague,It is our pleasure to welcome you to the Virtual Lynn Sage Breast Cancer Symposium. AlthoughCOVID-19 has prevented us from gathering in person, yet again, it is our privilege to once againbring together leaders in medical, surgical, and radiation oncology from around the world for threedays of compelling online presentations and interactive Q&A sessions.Hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, thisdynamic meeting has provided a forum for presenting and evaluating cutting-edge technologyand breast cancer treatment strategies since its inception in 1998. With a remarkable line-upof internationally recognized faculty and opportunities for people to engage in real-time followingtheir presentations, we are confident that this year’s virtual program will be no exception.We invite you to visit the virtual Exhibit Hall, accessible in the navigation bar of the symposiumwebsite. In addition, please follow and share updates on Twitter by following @LurieCancer andusing the hashtag #LSBC21.Thank you for participating in the 23rd Annual Lynn Sage Breast Cancer Symposium.Enjoy the program!Sincerely,William Gradishar, MDMonica Morrow, MD
PROGRAMINFORMATIONReferred to as the most valuable breast cancer meeting worldwide for the practicing clinician, the virtualLynn Sage Breast Cancer Symposium will provide 3 days of online presentations and interactive Q&A sessions.For over 20 years, this multidisciplinary CME program has provided the latest information regarding cutting-edgetechnology and approaches in the management of breast cancer from leading national and international medical,surgical, and radiation oncologists. This year’s virtual symposium will include a superb line-up of internationallyrecognized faculty who will not only present the latest research findings, but will also be available for real-timeinteraction following their presentations. The symposium will focus on the close cooperation required for effectivemultidisciplinary management of patients with breast cancer.EDUCATIONAL OBJECTIVES1. R ecognize social determinants of health thatimpact breast cancer care2. Discuss the genomic differences betweenpopulations that explain variation in diseasepatterns and tolerance to treatment5. D escribe surgical treatment options followingbreast recurrence in patients who previouslyunderwent breast conservation therapy6. D iscuss the opportunities and limitationsof next-generation sequencing (NGS)3. Summarize the impact of enhanced breast cancerrisk assessment using multiple genomic markers7. Discuss new systemic therapies for triplenegative breast cancer (TNBC)4. A pply genomic assays to make recommendationsfor adjuvant treatment in ER-positive, node-positiveand node- negative patient populations8. S ummarize the current role of CDK4/6inhibitors in early stage breast cancerTARGET AUDIENCEThe target audience for this activity includes medical oncologists, radiation oncologists, surgical oncologists, fellows intraining, oncology nurses and allied health professionals in breast cancer.23rd Annual LYNN SAGE BREAST CANCER SYMPOSIUM
SEPTEMBER 30THURSDAYSession 1: Disparities in Breast CancerModerator: Nora Hansen, MDSession 2: Breast Pathologyfor the Non-PathologistModerator: Kalliopi Siziopikou, MD, PhD9:00 amWelcomeWilliam Gradishar, MD9:10 amGenetic-Biologic Variation Based onCommon AncestryClayton Yates, PhD9:40 amVariation in the Care Experienceand Outcomes by RaceLisa Newman, MD, MPH10:10 amVariation in Toxicity by RaceMinoli Perera, PharmD, PhD10:40 amStrategies to Make ProgressRobert Winn, MD11:10 amQ&A11:40 amBreak & Exhibits11:40 amOptional Non-CME: Sponsored by SeagenTUKYSA (tucatinib): Clinical Trial Data1:00 pmHigh-Risk Pathologic Lesions of the Breast:Diagnosis and SignificanceKalliopi Siziopikou, MD, PhD1:30 pmTumor-Infiltrating Lymphocytes (TILs):Why Oncologists and Patients Need to Know?Roberto Salgado, MD, PhD2:00 pmFibroepithelial Lesions: Implications forDiagnosis and ManagementPuay Hoon Tan, FRCPA2:30 pmNext Generation Sequencing (NGS):Opportunities and LimitationsMark Burkard, MD, PhD3:00 pmQ&A3:20 pmOptional Non-CME: Sponsored by Gilead Sciences, Inc.Learn More About an FDA-Approved Treatment forMetastatic Triple-Negative Breast Cancer4:20 pmAdjourn23rd Annual LYNN SAGE BREAST CANCER SYMPOSIUM
OCTOBER 1FRIDAY8:00 amOptional Non-CME: Sponsored by PfizerClinical Trial Evidence for CDK4/6 InhibitorCombination Therapy Complemented by anEvaluation of Real-World EffectivenessSession 3: Imaging and RiskModerator: Seema Khan, MD9:00 amNovel Positron Emission Tomography (PET) TracersDavid Mankoff, MD, PhD9:30 amCan We Improve Breast Cancer Risk Assessment withMultiple Genomic Markers?Jeffrey Weitzel, MD10:00 amRisk Adapted Breast Cancer Screening?Fiona Gilbert, FRCR, FRCP(G), FRCP(E)10:30 amObesity and Breast Cancer RiskNeil Iyengar, MDSession 4: Emerging Treatment ModalitiesModerator: William Gradishar, MD1:10 pmIncorporating Immunotherapy into PracticeHeather McArthur, MD, MPH1:40 pmImmune BiomarkersElizabeth Mittendorf, MD, PhD2:10 pmCDK 4/6 InhibitorsSara Hurvitz, MD2:40 pmNon-immune Approaches to TNBCAditya Bardia, MD, MPH3:10 pmQ&A3:30 pmAdjourn11:00 amIs Breast Cancer Chemo-Prevention Dead?Seema Khan, MD11:30 amQ&A12:00 pmBreak & Exhibits12:00 pmOptional Non-CME: Sponsored by LillyA CDK 4 & 6 Inhibitor With Overall Survival Data forWomen With HR , HER2- Metastatic Breast Cancer,Including Those Likely To Do Worse23rd Annual LYNN SAGE BREAST CANCER SYMPOSIUM
OCTOBER 2SATURDAYSession 5: Complicated Local Therapy CasesSession 7: Difficult Clinical ProblemsModerator: Nora Hansen, MDModerator: Monica Morrow, MD7:45 amComplicated Local Therapy Cases:Management StrategiesLisa Flaum, MDSumanas Jordan, MD, PhDJonathan Strauss, MD, MBA1:10 pmSurgical Prevention and Treatment of LymphedemaDhruv Singhal, MDSession 6: Tailoring TherapyModerator: Jonathan Strauss, MD, MBA9:00 amManagement of the Breast and Axilla AfterNeoadjuvant Chemotherapy (NAC)Andrea Barrio, MD9:30 amSelecting Patients for Elimination of Radiotherapy (RT)Reshma Jagsi, MD, DPhil10:00 amWhen Can Axillary Surgery Be Eliminated?Tari King, MD, FACS10:30 amOptimizing Radiotherapy (RT)Philip Poortmans, MD, PhD11:00 amAdjuvant Therapy for ER , Node-PositiveBreast Cancer in 2021Harold Burstein, MD, PhD11:30 amQ&A12:00 pmBreak & Exhibits12:00 pmOptional Non-CME: Sponsored by GenentechCombining the HER2 Breast Cancer AntibodiesYou Know in One Faster Mode of Administration1:40 pmManagement of Recurrence After BreastConserving Therapy (BCT): What are the Options?Monica Morrow, MD2:10 pmSystemic Therapy Decisions in Older HR-PatientsHyman Muss, MD2:40 pmSalvage Surgery – How Effective Is It?Anita Mamtani, MD3:10 pmPrevention and Treatment of Brain TumorsNancy Lin, MD3:40 pmAdvances in the Treatment of HER2 Metastatic DiseaseWilliam Gradishar, MD4:10 pmQ&A4:45 pmAdjourn
CONFIRMEDFACULTYAditya Bardia, MD, MPHHarvard Medical SchoolDana-Farber Cancer InstituteAndrea Barrio, MDMemorial Sloan Kettering Cancer CenterMark Burkard, MD, PhDUniversity of WisconsinSchool of Medicine and Public HealthHal Burstein, MD, PhDHarvard Medical SchoolDana-Farber Cancer InstituteLisa Flaum, MDRobert H. Lurie Comprehensive CancerCenter of Northwestern UniversityFiona Gilbert, FRCR, FRCP(G), FRCP(E)University of CambridgeWilliam Gradishar, MDRobert H. Lurie Comprehensive CancerCenter of Northwestern UniversityNora Hansen, MDRobert H. LurieComprehensive Cancer Center ofNorthwestern UniversitySara Hurvitz, MDUniversity of California,Los AngelesNeil Iyengar, MDMemorial Sloan Kettering Cancer CenterReshma Jagsi, MD, DPhilUniversity of MichiganLisa Newman, MD, MPHWeill Cornell MedicineSumanas Jordan, MD, PhDNorthwestern UniversityFeinberg School of MedicineMinoli Perera, PharmD, PhDRobert H. Lurie Comprehensive CancerCenter of Northwestern UniversitySeema Khan, MDRobert H. LurieComprehensive Cancer Centerof Northwestern UniversityPhilip Poortmans, MD, PhDIridium NetwerkTari King, MD, FACSHarvard Medical SchoolDana-Farber Cancer InstituteNancy Lin, MDHarvard Medical SchoolDana-Farber Cancer InstituteAnita Mamtani, MDMemorial Sloan Kettering Cancer CenterDavid Mankoff, MD, PhDUniversity of PennsylvaniaHeather McArthur, MD, MPHCedars-SinaiElizabeth Mittendorf, MD, PhDHarvard Medical SchoolDana-Farber Cancer InstituteMonica Morrow, MDMemorial Sloan Kettering Cancer CenterHyman Muss, MDUniversity of North Carolina School ofMedicineRoberto Salgado, MD, PhDGZA-ZNA HospitalsDhruv Singhal, MDHarvard Medical SchoolDana-Farber Cancer InstituteKalliopi Siziopikou, MD, PhDRobert H. Lurie Comprehensive CancerCenter of Northwestern UniversityJonathan Strauss, MD, MBARobert H. Lurie Comprehensive CancerCenter of Northwestern UniversityPuay Hoon Tan, FRCPASingapore General HospitalJeffrey Weitzel, MDLatin American School of OncologyRobert Winn, MDVCU Massey Cancer CenterVirginia Commonwealth UniversityClayton Yates, PhDTuskegee University23rd Annual LYNN SAGE BREAST CANCER SYMPOSIUM
DISCLOSUREDECLARATIONSFACULTY / SPEAKER DISCLOSUREStatement and Disclosure for Discussionsof Off-Label / Investigational Use ofPharmaceutical ProductsIDENTIFYING CONFLICT OF INTEREST:A six-tier peer review system has been developedto identify possible conflicts of interests.» The first tier is the SpeakerIn accordance with ACCME Standards for CommercialSupport of Continuing Medical Education and the FeinbergSchool of Medicine’s disclosure policy for CME activities,all individuals who contribute to the content or theidentification/resolution of potential conflicts of interestmust disclose any relationship they may have with anyentity producing, marketing, re-selling, or distributinghealth care goods or services consumed by, or used on,patients within the preceding 12 months of the activity.» The second-tier is the Course Director and/orPlanning Committee MembersSuch disclosure is intended to provide participantswith sufficient information to evaluate whether anygiven presentation has been influenced by the faculty’srelationships(s) or financial interest with said companies.» The sixth-tier is the CME CoordinatorCircumstances create a conflict of interest when anindividual has an opportunity to affect CME content aboutproducts or services of a commercial interest with which he/she has a financial relationship. The purpose for identifyingand addressing potential conflicts of interest is to ensurea proper balance, independence, objectivity, and scientificrigor of the medical school’s educational activities. Themedical school does not view the existence of a financialrelationship as necessarily implying bias or decreasing thevalue of participation in CME activities, but must ensure thata financial interest is not a conflict of interest.Clara Schroedl, MD, Medical Director of CMEHas nothing to disclose.» The third-tier is the CME Director» The fourth-tier is the CME Review Committee» The fifth-tier is the CME Medical DirectorFSM’S CME LEADERSHIP AND STAFFSheryl Corey, CME DirectorHas nothing to disclose.Allison McCollum, Senior Program CoordinatorHas nothing to disclose.Rhea Alexis Banks, Administrative Assistant 2Has nothing to disclose.This activity is being sponsored by the Feinberg School ofMedicine, Robert H. Lurie Comprehensive Cancer Centerof Northwestern University. The medical school has nosignificant relationship with the commercial companieswhose products are services are being discussed in thiseducational activity.Kathleen Harken, Administrative Director of theRobert H. Lurie Comprehensive Cancer Center,has nothing to disclose.The staff of Meeting Achievements have no financialrelationships to disclose.23rd Annual LYNN SAGE BREAST CANCER SYMPOSIUM
DISCLOSUREDECLARATIONSCOURSE FACULTY DISCLOSURESAditya Bardia, MD, MPH has receivedconsulting fees from Novartis AG, Pfizer,Inc., Merck and Company, Inc., Genentech/Roche, Sanofi-Aventis, Astra-Zeneca,Radius Health, Immunomedics,Foundation Medicine, and Daiichi Sankyo.Nancy Lin, MD has received consulting feesfrom AstraZeneca, Daiichi Sankyo,Seattle Genetics, Denali Therapeutics, andPrelude Therapeutics, and has contractedresearch with Merck and Company, Inc.,Seattle Genetics, and Genentech.The following individualshave disclosed no relevantfinancial relationships:Mark Burkard, MD, PhD has contractedresearch with Abbvie, Biomed Valley,Genentech, Puma, Arcus, Apollomics,Bayer Corporation, Loxo Oncology/Lilly,Elevation Oncology; he has also served onthe medical advisory board and receivedconsulting fees from Strata Oncology.David Mankoff, MD, PhD has ownershipinterest in Reflexion, ImaginAB, and Trevarx;he has also received consulting fees fromGE Healthcare Bio-Sciences and PhilipsMedical Systems, Inc.Harold Burstein, MD, PhDHeather McArthur, MD, MPH has receivedconsulting fees from Seattle Genetics,AstraZeneca, Eli Lilly and Company,Merck and Company, Inc., and hascontracted research with Bristol-MyersSquibb and Merck and Company, Inc.Sumanas Jordan, MD, PhDElizabeth Mittendorf, MD, PhD hasreceived consulting fees from Merck andCompany, Inc., Roche, and Genomic Health(now Exact Sciences).Minoli Perera, PharmD, PhDLisa Flaum, MD has served on the SpeakersBureau for Novartis AG and Seattle Genetics.Fiona Gilbert, FRCR, FRCP(G), FRCP(E)has received consulting fees from GoogleDeep Mind and research support from GEHealthcare Bio-Sciences, GlaxoSmithKline,and Bayer Corporation.Sara Hurvitz, MD has contracted researchwith Ambrx, Amgen, Astra Zeneca,Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly,Macrogenics, Novartis, Pfizer, OBI Pharma,Pieris, PUMA, Radius, Sanofi,Seattle Genetics, Dignitana, Zymeworks,and Phoenix Molecular Designs, Ltd.Neil Iyengar, MD has received consultingfees from Novartis AG and Seattle Geneticsand has contracted research withNovartis AG.Tari King, MD, FACS has received honorariafrom Presica Cancer Information Serviceand served on the advisory board forBesins Healthcare Limited Ireland Ltd andExact Sciences, formerly Genomic Health.Monica Morrow, MD has receivedspeaking honoraria from Roche.Philip Poortmans, MD, PhD is amedical advisor for S.I.T. SordinaIORT Technologies, S.p.A.Andrea Barrio, MDKevin Bethke, MDWilliam Gradishar, MDNora Hansen, MDReshma Jagsi, MD, DPhilSeema Khan, MDAnita Mamtani, MDHyman Muss, MDLisa Newman, MD, MPHRobert Salgado, MD, PhDDhruv Singhal, MDPuay Hoon Tan, FRCPARobert Winn, MDClayton Yates, PhDAmi Shah, MD has received consultingfees from AstraZeneca and honorariumfrom Taiho.Kalliopi Siziopikou, MD,PhD has receivedhonorarium from Merck and Company, Inc.and Eli Lilly and Company.Jonathan Strauss, MD, MBA has receivedconsulting fees from American ImagingManagement.Jeffrey Weitzel, MD has served onthe Speakers Bureau for AstraZeneca.23rd Annual LYNN SAGE BREAST CANCER SYMPOSIUM
23RD ANNUAL LYNN SAGE BREAST CANCER SYMPOSIUMACKNOWLEDGEMENTSThis course is supported in part by educational grants from:PATRON3MAstraZeneca PharmaceuticalsDaiichi Sankyo, Inc.Gilead OncologyLilly USA, LLCNovartis Pharmaceuticals CorporationPfizerPuma Biotechnology, Inc.WE THANK OUR EXHIBITORS & SPONSORSGOLDSILVERBRONZEGenentech,A Member of the Roche GroupAgendia, Inc.AstraZenecaEisai Inc.Merck & Co. incPfizerPuma Biotechnology, Inc.Seagen Inc.All of Us Research ProgramAmgen. Inc.Breast Cancer Patient ConnectDaiichi SanykoEli LillyExact Sciences CorporationGilead OncologyLiving Well Cancer Resource CenterNovartisTEMPUSSPONSORS OF THE LYNN SAGE BREAST CANCER SYMPOSIUMSNACKSGilead OncologyMUSIC BREAKNational Accreditation Programfor Breast Cancers
Jonathan Strauss, MD, MBA SYMPOSIUM CHAIR William Gradishar, MD SYMPOSIUM CO-CHAIR Monica Morrow, MD 23RD ANNUAL LYNN SAGE BREAST CANCER SYMPOSIUM SEPTEMBER 30 - OCTOBER 2, 2021 VISIT OUR WEBSITE lynnsagebreastcancer.org VIRTUAL FOR 2021
